

<b>NEW FDA DRUGS AND WARNINGS NOT FITTING NIOSH CRITERIA FOR HAZARDOUS DRUGS 2006</b>							
<u>Proprietary Name</u>	<u>Established Name</u>	<u>NIOSH Hazardous Drugs Criteria</u>					<u>How Supplied</u>
		<u>Cancer</u>	<u>Preg Cat</u>	<u>Repro Tox</u>	<u>Organ Tox</u>	<u>Geno Tox</u>	
Actoplus Met	pioglitazone HCl/metformin HCl	NT	C	NT	+	NT	Tablets
Actos	pioglitazone HCl	--/+	C	--	+	--	Tablets
Adderall	amphetamines	--	C	--	+	--	Tablets
Amphadase*	hyaluronidase	NT	C	NT		NT	Dermal injection
Apidra	insulin glulisine	+	C	--		--	Subcutaneous injection or infusion
Aptivus	tipranivir	In progress	C	--	+	--	Capsules
Aranesp	darbepoetin alfa		C		+		IV injection
Avandaryl	rosiglitazone maleate/Glimepiride	+/--	C	+/--	+	+/--	Tablets
Avonex	interferon beta 1a	NT	C	+/--		--	IM injection
Betaseron	interferon beta 1b	NT	C	+/--		--	Subcutaneous injection
Byetta	exenatide	--	C			--	Subcutaneous Injection
Campral	acamprosate calcium	--	C	--		--	Coated tablets
Cancidis	caspofungin acetate	NT	C	--	--	--	IV infusion
ChiRhoStim	human secretion	NT	C	NT		NT	IV Injection
Clozaril	clozapine	-	B			-	Tablets
Concerta*	methylphenidate HCl	+/--	C	--	+	+/--	Tablets
Cymbalta	doloxetine HCl	+/--	C	+/--	--	--	Coated capsules
Daytrana*	methylphenidate HCl	+/--	C	--	+	+/--	Trans-dermal
Dexedrine	dextroamphetamine	NT	C		+	NT	Tablets
Dilaudid	hydromorphone HCl	NT	C	--		--	Tablets
Diovan	valsartan	--	C	--		--	Tablets
Elaprase	idursulfate	NT	C	NT		NT	IV infusion
Elmiron	pentosan polysulfate Na	--	B	NT		--	Capsules
Elspar	asparaginase	--	C	NT	+	--	IV
Enablex	darifenacin HBr	--	C	--		--	Coated tablets
Epogen*	epoetin alfa	NT	C		+	--	IV injection
Eraxis	andulafungin	NT	C	--		--	IV Infusion
Ethyol	amifostine	NT	C	NT	+	+/-	IV infusion
Exjade	deferasirox	--	B		--	--	Tablets for oral suspension

<b>NEW FDA DRUGS AND WARNINGS NOT FITTING NIOSH CRITERIA FOR HAZARDOUS DRUGS 2006</b>							
<u>Proprietary Name</u>	<u>Established Name</u>	<u>NIOSH Hazardous Drugs Criteria</u>					<u>How Supplied</u>
		<u>Cancer</u>	<u>Preg Cat</u>	<u>Repro Tox</u>	<u>Organ Tox</u>	<u>Geno Tox</u>	
Focalin	dexmethyphenidate HCl	+/--	C	--	+	+/--	Tablets
Fortovase	saquinavir mesylate	--	B	--	+	--	Capsules
Fosrenol	lanthanum carbonate hydrate	+/--	C	+/--			Chewable tablet
Gabitril	tiagabine	+/--	C	+/--		+/--	Tablets
Herceptin	trastuzumab	NT	B	--	+	--	IV infusion
Humira	adalimumab	+	B		+		Subcutaneous injection
Hydase*	hyaluronidase	NT	C	NT		NT	
Invirase*	saquinavir mesylate	--	B	--	+	--	Tablets, capsules
Iplex	mecasermin rinfabate	NT	C	NT		NT	Subcutaneous injection
Januvia	sitagliptin phosphate	+	B	--		--	Tablets
Ketek	telithromycin	NT	C	+/--	+	--	Tablets
Lamictal	lamotrigine	--	C	--	+	--	Tablets
Levemir	insulin detemir	NT	C	+/--		--	Subcutaneous Injection
Lucentis	ranibizumab	NT	C	NT		NT	Intravitreal injection
Lumigan	bimatoprost	--	C	--		--	Ophthalmic
Macugen	pegaptanib sodium	NT	B	--		--	Intravitreal Injection
Magnevist	gadopentetate dimeglumine	NT	C	+		+/--	IV
Metadate*	methylphenidate HCl	+/--	C	--	+	+/--	Tablets
Methylin*	methylphenidate HCl	+/--	C	--	+	+/--	Tablets
Multihance	gadobenate dimeglumine	NT	C	+/--		--	
Naglazyme	galsulfase	NT	B	--		NT	IV Infusion
Nevanac	nepafenac	NT	C			--	Ophthalmic suspension
Nexium	esomeprazole magnesuim	+/--	B	--		+	Capsules
Noxafil	posaconazole	--	C	--	+	--	Oral suspension
NutreStore	L-glutamine	NT	C	NT		NT	
Omacor	omega-3-acide ethylesters	--	C	--		--	Capsules
Opana	oxymorphone HCl	--	C	+		+/--	Tablets
Pentetate Zinc Trisodium		NT	B	NT		NT	IV injection
Prevacid NapralPAC	lansoprazole/ naproxen	+	C	--	+	+	Capsules

**NEW FDA DRUGS AND WARNINGS NOT FITTING NIOSH CRITERIA FOR HAZARDOUS DRUGS 2006**

<u>Proprietary Name</u>	<u>Established Name</u>	<u>NIOSH Hazardous Drugs Criteria</u>					<u>How Supplied</u>
		<u>Cancer</u>	<u>Preg Cat</u>	<u>Repro Tox</u>	<u>Organ Tox</u>	<u>Geno Tox</u>	
Prezista	darunavir	NT	B	--		--	Tablets
Prialt	ziconotide	NT	C	+/--	+	--	Intrathecal infusion
Procrit*	epoetin alfa	NT	C		+	--	IV injection
Propranolol HCl	inderal	--	C	--		+/--	IV
Ranexa	ranolazine	+/--	C	NT		--	Coated tablets
Rapamune	sirolimus	+	C	+/--		--	tablets
Raptiva	efalizumab	NT	C	+/--			Subcutaneous injection
Remicade	infliximab	+/--	B	--	+	--	IV infusion
Ritalin*	methylphenidate HCl	+/--	C	--	+	+/--	Capsules
Sanctura	tropium chloride	--	C	--		--	Tablets
Serzone	nefazodone HCl		C		+		Tablets
Sensipar	cinacalcet HCl	--	C	NT		--	Tablets
Strattera	atmozetina HCl	--	C	--	+	--	Tablets
Symlin	pramlintide acetate	--	C	--		--	Subcutaneous injection
Trasylol	aprotinin	NT	B			--	IV injection
Tyzeka	telbivudine	--	B	--		--	Tablets
Vectibix	panitumumab	NT	C	+	+	NT	IV
Ventavis	iloprost	--	C	--		--	Inhalation
Veregen	kunecatechins	--	C	--		+	Ointment
VESIcare	solifenacin succinate	--	C	--		--	Tablets
Videx	didanosine	--	B	--	+	+	Tablets
Visudyne	verteporfin	NT	C			+	IV infusion
Vitrase	ovine hyaluronidase	NT	C	NT			Dermal injection
Wellbutrin*	bupropion HCl	--	C	--	--	+	Tablets
Xifaxan	rifaximin	NT	C	--		--	Tablets
Zarontin	ethosuximide				+		Capsules
Zinecard	dextrazoxane	NT	C	+	+		IV infusion
Zyban*	bupropion HCl	--	C	--	--	+	Tablets
Zyprexa	olanzapine	+	C	+		-	Tablets

Drugs include new FDA approved drugs from 2004-2006; new FDA drug warnings 2006; NIH Hazardous Drugs List

<b>NEW FDA DRUGS AND WARNINGS NOT FITTING NIOSH CRITERIA FOR HAZARDOUS DRUGS 2006</b>							
<u>Proprietary Name</u>	<u>Established Name</u>	<u>NIOSH Hazardous Drugs Criteria</u>					<u>How Supplied</u>
		<u>Cancer</u>	<u>Preg Cat</u>	<u>Repro Tox</u>	<u>Organ Tox</u>	<u>Geno Tox</u>	
NT = Not Tested; + = characteristic of drug fits NIOSH definition; -- = characteristic of drug does not fit NIOSH definition; +/- = mixed characteristics; * = more than one proprietary name for same drug							
Pregnancy Category A women fail to demonstrate a risk to the fetus in the first trimester (and there is no evidence of a risk in later trimesters), and the possibility of fetal harm appears remote.						Controlled studies in	
Pregnancy Category B reproduction studies have not demonstrated a fetal risk but there are no controlled studies in pregnant women, or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the first trimester (and there is no evidence of a risk in later trimesters).						Either animal-	
Pregnancy Category C animals have revealed adverse effects on the fetus (teratogenic or embryocidal or other) and there are no controlled studies in women, or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus.						Either studies in	
Pregnancy Category D evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).						There is positive	
Pregnancy Category X or human beings have demonstrated fetal abnormalities, or there is evidence of fetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.						Studies in animals	